Latest Breaking News On - University of pittsburgh medical center - Page 27 : comparemela.com

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | Company Announcement

Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

United statesThomask equelsRobert edwardsUniversity of pittsburgh medical centerGynecology reproductive sciencesGynecologic oncology research at magee womens hospitalExchange commissionImmunotech incDepartment of obstetricsTech announces positive top lineProtocol planned interim report dataAmpligen combinedRecurrent ovarianImmune checkpoint blockadePittsburgh medical centerObjective response rate

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have.

United statesRobert edwardsThomask equelsExchange commissionDepartment of obstetricsImmunotech incGynecologic oncology research at magee womens hospitalUniversity of pittsburgh medical centerGynecology reproductive sciencesImmune checkpoint blockadeRecurrent ovarianPittsburgh medical centerObjective response rateClinical benefit rateProgression free survivalReproductive sciences

MedQuest Names Aalpen Patel Chief Clinical and Innovation Officer

MedQuest Names Aalpen Patel Chief Clinical and Innovation Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJason howardSandy hattendorfUniversity of pittsburgh medical centerBucknell universityUniversity of texas md anderson cancer centerMedquest associatesStevens institute of technologyGeisinger commonwealth school of medicineLeadership councilSociety of interventional radiologyTemple university hospitalSteele institute for health innovation at geisingerRutgers university robert wood johnson medical schoolQuest associatesAalpen patel

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomask equelsRobert edwardsDepartment of obstetricsImmunotech incGynecologic oncology research at magee womens hospitalGynecology reproductive sciencesUniversity of pittsburgh medical centerImmune checkpoint blockadeRecurrent ovarianPittsburgh medical centerObjective response rateClinical benefit rateProgression free survivalReproductive sciencesGynecologic oncology research

European Urology Names Fox Chase Cancer Center s Dr Andres F Correa Reviewer of the Month

The journal European Urology has named Fox Chase Cancer Center urologic oncologist Andres F. Correa, MD, its March 2024 Reviewer of the Month.

United statesFox chase cancer centerFox chaseAndresf correaAlexander kutikovUniversity of maryland school medicineAmerican urological associationSociety of urologic oncologySociety of urologic oncology fellowship directorNational hispanic medical associationUniversity of pittsburgh medical centerDepartment of urologyAmerican medical associationEuropean urologyAssistant professorUrologic oncology